<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04711200</url>
  </required_header>
  <id_info>
    <org_study_id>P150941J</org_study_id>
    <nct_id>NCT04711200</nct_id>
  </id_info>
  <brief_title>LYell SYndrome MEsenchymal Stromal Cells Treatment</brief_title>
  <acronym>LYSYME</acronym>
  <official_title>Mesenchymal Stromal Cells Treatment in Lyell Syndrome: A Pilot Phase 1-2 Open Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Assistance Publique - Hôpitaux de Paris</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Assistance Publique - Hôpitaux de Paris</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) are rare severe cutaneous&#xD;
      adverse reactions (SCARs) to drugs.&#xD;
&#xD;
      To date, no curative drug has demonstrated with a good level of evidence its ability to&#xD;
      promote SJS and TEN healing and could contribute to earlier reepithelialisation. Mesenchymal&#xD;
      stroma cells (MSCs) therapy represents a new therapeutic approach. eg, in patients with&#xD;
      cardiovascular diseases, neurological diseases, renal transplantation, lung diseases as acute&#xD;
      respiratory distress syndrome.&#xD;
&#xD;
      Recently, MSCs have been proposed in both burn wound healing with a significantly decrease of&#xD;
      the unhealed burn area and in cutaneous radiation.&#xD;
&#xD;
      Moreover, MSCs have immunomodulation properties potentially effective in refractory acute and&#xD;
      chronic graft versus host disease (GVHD) by improving thymic function and induction of Tregs.&#xD;
      Indeed, MSCs are able to migrate to inflamed tissues after stimulation by pro-inflammatory&#xD;
      cytokines and to modulate the local inflammatory reactions. MSCs have also demonstrated their&#xD;
      ability to promote tissue remodelling, angiogenesis and immunomodulation through either&#xD;
      differentiation or secretion of several growth factors such as VEGF, basic FGF and various&#xD;
      cytokines.&#xD;
&#xD;
      Therefore, combining their immunomodulation effect and secretion of soluble factors involved&#xD;
      in wound repair, MSCs might be valuable as a cell therapy strategy for promoting cutaneous&#xD;
      healing in SJS-TEN syndrome and subsequently decrease the morbi-mortality.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">January 2022</start_date>
  <completion_date type="Anticipated">January 2025</completion_date>
  <primary_completion_date type="Anticipated">January 2025</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety : Observation of at least one adverse effect</measure>
    <time_frame>Day 10</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Efficacy : Rate of complete or almost complete reepithelialisation</measure>
    <time_frame>Day 7 after infusion</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Rate of observed and predicted death by the SCORTEN</measure>
    <time_frame>at one month</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of hospitalisation according to our historical cohort related to BSA involved</measure>
    <time_frame>Month 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of hospitalisation according to our historical cohort related to onset of the disease</measure>
    <time_frame>Month 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of hospitalisation according to our historical cohort related to SCORTEN</measure>
    <time_frame>Month 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of each mucous membranes healing ie.(buccal, nasal, genital, eyes)</measure>
    <time_frame>at Month 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of sepsis</measure>
    <time_frame>at Month 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of intensive care transfer</measure>
    <time_frame>at Month 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of sequelae</measure>
    <time_frame>at Month 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Th1/Th2 immune response in the peripheral blood of the patients</measure>
    <time_frame>after injection at Day 0, Day 10, Month 1</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluation of expression profile of Th1/Th2 associated chemokines and anti-inflammatory chemokines in the peripheral blood</measure>
    <time_frame>after injection at Day 0, Day 10, Month 1.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Epidermal chimerism study on healed skin biopsy</measure>
    <time_frame>at 1 month</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cutaneous re-epithelialization rate at D5, D10 and D15 post-infusion according to the percentage of cutaneous BSA re-epithelialized in comparison to maximal cutaneous detachable-detached BSA observed.</measure>
    <time_frame>at Day 5, Day 10 and Day15</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">15</enrollment>
  <condition>Epidermal Necrolysis</condition>
  <condition>Lyell Syndrome</condition>
  <condition>Toxic Epidermal Necrolysis</condition>
  <condition>Overlap Syndrome</condition>
  <condition>Mesenchymal Stromal Cells</condition>
  <condition>Adipose Derived Stromal Cells</condition>
  <arm_group>
    <arm_group_label>Adipose derived stromal cells intravenously injected</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Adipose derived stromal cells intravenously injected</intervention_name>
    <description>2×10^6/kg of Adipose derived stromal cells A single injection at D0 (performed maximum three days post-admission).</description>
    <arm_group_label>Adipose derived stromal cells intravenously injected</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients aged from 18 to 75 years-old&#xD;
&#xD;
          -  Admission less than 10 days after onset of the reaction&#xD;
&#xD;
          -  Patient with confirmed SJS-TEN diagnosis hospitalized in the department of Dermatology&#xD;
             or intensive care medicine&#xD;
&#xD;
          -  At least 10 % of detachable-detached body surface area at any time during the first 10&#xD;
             days after the index date (date of the first symptoms of the disease)&#xD;
&#xD;
          -  Written consent from patient or trustworthy person or legal representant or family&#xD;
             member&#xD;
&#xD;
          -  Affiliated to a social security scheme&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Pregnant or breastfeeding women&#xD;
&#xD;
          -  History of malignant disease within the past ten years and or presence of metastasis&#xD;
&#xD;
          -  Positive serology for HIV&#xD;
&#xD;
          -  Active infection for hepatitis B or C&#xD;
&#xD;
          -  Decompensated cardiac failure&#xD;
&#xD;
          -  Uncontrolled epilepsia&#xD;
&#xD;
          -  Previous history of allogenic bone marrow transplantation&#xD;
&#xD;
          -  Participation in other interventional drug research&#xD;
&#xD;
          -  Patient deprived of liberty by a judicial or administrative decision or under the&#xD;
             protection of justice&#xD;
&#xD;
          -  Any psychological, familial, sociological or geographical condition potentially&#xD;
             hampering compliance with the research protocol and follow-up schedule&#xD;
&#xD;
          -  Patient under tutorship or curatorship&#xD;
&#xD;
          -  Patient under psychiatric care according to art. L1121-6 CSP&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Saskia Oro, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>saskia.oro@aphp.fr</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Saskia Oro, MD</last_name>
    <phone>0149812536</phone>
    <phone_ext>+33</phone_ext>
    <email>saskia.oro@aphp.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Myriem Carrrier, MSc</last_name>
    <phone>0144841752</phone>
    <email>myriem.carrier@aphp.fr</email>
  </overall_contact_backup>
  <reference>
    <citation>Mockenhaupt M, Viboud C, Dunant A, Naldi L, Halevy S, Bouwes Bavinck JN, Sidoroff A, Schneck J, Roujeau JC, Flahault A. Stevens-Johnson syndrome and toxic epidermal necrolysis: assessment of medication risks with emphasis on recently marketed drugs. The EuroSCAR-study. J Invest Dermatol. 2008 Jan;128(1):35-44. Epub 2007 Sep 6.</citation>
    <PMID>17805350</PMID>
  </reference>
  <reference>
    <citation>Creamer D, Walsh SA, Dziewulski P, Exton LS, Lee HY, Dart JK, Setterfield J, Bunker CB, Ardern-Jones MR, Watson KM, Wong GA, Philippidou M, Vercueil A, Martin RV, Williams G, Shah M, Brown D, Williams P, Mohd Mustapa MF, Smith CH. U.K. guidelines for the management of Stevens-Johnson syndrome/toxic epidermal necrolysis in adults 2016. Br J Dermatol. 2016 Jun;174(6):1194-227. doi: 10.1111/bjd.14530.</citation>
    <PMID>27317286</PMID>
  </reference>
  <reference>
    <citation>Roux S, Leotot J, Chevallier N, Bierling P, Rouard H. [Mesenchymal stromal cells: Biological properties and clinical prospects]. Transfus Clin Biol. 2011 Feb;18(1):1-12. doi: 10.1016/j.tracli.2011.01.001. Epub 2011 Mar 1. French.</citation>
    <PMID>21367635</PMID>
  </reference>
  <reference>
    <citation>Chung HM, Won CH, Sung JH. Responses of adipose-derived stem cells during hypoxia: enhanced skin-regenerative potential. Expert Opin Biol Ther. 2009 Dec;9(12):1499-508. doi: 10.1517/14712590903307362. Review.</citation>
    <PMID>19780713</PMID>
  </reference>
  <results_reference>
    <citation>Duong TA, Valeyrie-Allanore L, Wolkenstein P, Chosidow O. Severe cutaneous adverse reactions to drugs. Lancet. 2017 Oct 28;390(10106):1996-2011. doi: 10.1016/S0140-6736(16)30378-6. Epub 2017 May 2. Review. Erratum in: Lancet. 2017 Oct 28;390(10106):1948.</citation>
    <PMID>28476287</PMID>
  </results_reference>
  <verification_date>November 2020</verification_date>
  <study_first_submitted>November 30, 2020</study_first_submitted>
  <study_first_submitted_qc>January 12, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">January 15, 2021</study_first_posted>
  <last_update_submitted>September 27, 2021</last_update_submitted>
  <last_update_submitted_qc>September 27, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 28, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Epidermal necrolysis</keyword>
  <keyword>Lyell syndrome</keyword>
  <keyword>toxic epidermal necrolysis</keyword>
  <keyword>Overlap syndrome</keyword>
  <keyword>Mesenchymal stromal cells</keyword>
  <keyword>Adipose derived stromal cells</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Stevens-Johnson Syndrome</mesh_term>
    <mesh_term>Syndrome</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

